Aileron Therapeutics, Inc. (ALRN)
NASDAQ: ALRN · IEX Real-Time Price · USD
5.00
+0.01 (0.20%)
Apr 25, 2024, 3:59 PM EDT - Market closed

Aileron Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018201720162015
Cash & Equivalents
17.345.223.637.645.3410.6611.9520.83.83
Short-Term Investments
016.0542.336.7612.9710.0638.8900
Cash & Cash Equivalents
17.3421.2745.9614.418.320.7250.8420.83.83
Cash Growth
-18.47%-53.73%219.20%-21.34%-11.67%-59.24%144.39%443.02%-
Other Current Assets
0.930.612.221.931.251.0610.270.2
Total Current Assets
18.2721.8748.1816.3319.5521.7851.8421.074.03
Property, Plant & Equipment
0.020.110.280.026.367.290.150.110.35
Long-Term Investments
00000.570.57000
Goodwill and Intangibles
85.5300000000
Other Long-Term Assets
2.190.020.02000.680.690.841.56
Total Long-Term Assets
87.740.130.30.026.928.540.850.951.91
Total Assets
106.0122.0148.4816.3426.4730.3152.6922.025.94
Accounts Payable
1.191.721.211.61.451.731.61.970.64
Current Debt
0.050.030.090.170.450000
Other Current Liabilities
3.151.633.212.23.943.643.292.11.91
Total Current Liabilities
4.393.384.513.965.845.374.894.072.55
Long-Term Debt
000.070.224.595.34000
Other Long-Term Liabilities
3.330000000.010.03
Total Long-Term Liabilities
3.3300.070.224.595.3400.010.03
Total Liabilities
7.713.384.584.1810.4310.714.894.082.58
Total Debt
0.050.030.160.395.035.34000
Debt Growth
45.45%-79.63%-58.14%-92.31%-5.80%----
Retained Earnings
-288.52-272.79-245.46-219.29-198.14-168.49-136.95-114.34-96.22
Comprehensive Income
-0.06-0.05-0.01-00.01-0.01-0.0300
Shareholders' Equity
6.8918.6243.912.1616.0519.647.8-111.81-94.32
Net Cash / Debt
17.2921.2345.814.0113.2715.3850.8420.83.83
Net Cash / Debt Growth
-18.57%-53.63%226.86%5.58%-13.70%-69.75%144.39%443.02%-
Net Cash Per Share
3.764.6810.318.0410.8220.87136.61968.30191.21
Working Capital
13.8818.4943.6712.3713.7116.4146.95171.48
Book Value Per Share
1.504.109.896.9813.0826.60128.43-5204.08-4707.56
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).